Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

263 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial.
Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, Baruchel A, Boyer M, De Moerloose B, Qayed M, Buechner J, Pulsipher MA, Myers GD, Stefanski HE, Martin PL, Nemecek E, Peters C, Yanik G, Khaw SL, Davis KL, Krueger J, Balduzzi A, Boissel N, Tiwari R, O'Donovan D, Grupp SA. Laetsch TW, et al. Among authors: pulsipher ma. J Clin Oncol. 2023 Mar 20;41(9):1664-1669. doi: 10.1200/JCO.22.00642. Epub 2022 Nov 18. J Clin Oncol. 2023. PMID: 36399695 Free PMC article. Clinical Trial.
Use of G-CSF in matched sibling donor pediatric allogeneic transplantation: a consensus statement from the Children's Oncology Group (COG) Transplant Discipline Committee and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive Committee.
Grupp SA, Frangoul H, Wall D, Pulsipher MA, Levine JE, Schultz KR. Grupp SA, et al. Among authors: pulsipher ma. Pediatr Blood Cancer. 2006 Apr;46(4):414-21. doi: 10.1002/pbc.20800. Pediatr Blood Cancer. 2006. PMID: 16463346 Review.
A prospective study of G-CSF primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium (PBMTC) study.
Frangoul H, Nemecek ER, Billheimer D, Pulsipher MA, Khan S, Woolfrey A, Manes B, Cole C, Walters MC, Ayas M, Ravindranath Y, Levine JE, Grupp SA. Frangoul H, et al. Among authors: pulsipher ma. Blood. 2007 Dec 15;110(13):4584-7. doi: 10.1182/blood-2007-07-101071. Epub 2007 Sep 7. Blood. 2007. PMID: 17827386 Free article. Clinical Trial.
Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse.
Pulsipher MA, Bader P, Klingebiel T, Cooper LJ. Pulsipher MA, et al. Biol Blood Marrow Transplant. 2009 Jan;15(1 Suppl):62-71. doi: 10.1016/j.bbmt.2008.11.009. Biol Blood Marrow Transplant. 2009. PMID: 19147081 Free article. Review.
Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313.
Pulsipher MA, Boucher KM, Wall D, Frangoul H, Duval M, Goyal RK, Shaw PJ, Haight AE, Grimley M, Grupp SA, Kletzel M, Kadota R. Pulsipher MA, et al. Blood. 2009 Aug 13;114(7):1429-36. doi: 10.1182/blood-2009-01-196303. Epub 2009 Jun 15. Blood. 2009. PMID: 19528536 Free article. Clinical Trial.
263 results